Natera Shares Jump 5.36% on $230M Volume (Rank 464th) as Oncology Growth and Medicare Expansion Fuel Momentum

On September 9, 2025, , ranking 464th in market activity. The stock's performance followed the company's strategic updates at the Morgan Stanley Global Healthcare Conference, where it highlighted robust growth in oncology and organ health. Natera reported record patient volumes for its Signatera assay, a key driver of revenue, and emphasized progress in expanding Medicare reimbursement for the product.

The firm underscored its leadership in (NIPT) with over 50% market share and positive clinical data from the INVICTER trial in bladder cancer. Natera also outlined plans to leverage its extensive data to develop for pharmaceutical partnerships. Financially, , supporting its innovation and expansion strategies, including a potential 2027 launch in Japan with higher pricing potential.

Operational momentum includes a record number of new Signatera patients in the latest quarter, with approximately half of U.S. physicians using the test quarterly. The company is targeting improved compliance and state-level biomarker laws to boost average selling prices (ASPs) for Signatera, . Future initiatives include a test based on the Proceed study and expansion into adjuvant therapy trials, where molecular residual disease detection could redefine treatment paradigms.

For back-test parameters: 1. Universe of stocks – specify U.S. listed common stocks (~6,000) or S&P 500. 2. Trade-execution convention – confirm preference for ranking by dollar volume and executing trades at next-day open/close. Clarification on these details will enable a precise 2022-01-03 to present back-test analysis.